Update on house dust mite immunotherapy: are more studies needed?

Area of Science:

• Allergy and Immunology
• Immunotherapy Research
• Respiratory Medicine

Background:

• Systematic reviews confirm the efficacy of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for allergic rhinitis and asthma.
• A gap exists in consensus regarding optimal treatment parameters for house dust mite (HDM) immunotherapy.

Purpose of the Study:

• To review recent studies on immunotherapy using house dust mite (HDM) extracts.
• To evaluate the efficacy and safety of HDM immunotherapy, focusing on SCIT and SLIT.

Main Methods:

• Review of nine recently published studies on HDM immunotherapy.
• Analysis of studies involving both SLIT (six studies) and SCIT (three studies).
• Focus on allergic rhinitis and allergic asthma treatment outcomes.

Main Results:

• Six studies demonstrated the efficacy of HDM-SLIT for allergic rhinitis and asthma.
• Three studies confirmed the efficacy of HDM-SCIT for pediatric allergic asthma.
• Safety data for HDM immunotherapy were generally reassuring, particularly for SLIT.

Conclusions:

• Recent evidence supports the efficacy of HDM-SLIT for allergic rhinitis and asthma, and HDM-SCIT for pediatric asthma.
• While safety is reassuring, particularly for SLIT, dosing information for liquid SLIT requires standardization for clinical practice.
• Ongoing trials for HDM-SLIT tablets aim to establish optimal doses through large-scale, randomized, placebo-controlled studies.